knowledge -WSS

knowledge

author：explore 2025-10-01 10:59:34 - browse：285

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Pfizer's Covid pill remains 89% effective in final analysis, company says

focus

WSS

Democrats decry new health bill for going easy on private equity

New Alzheimer's drugs heat up race for early detection blood tests

The battle over 'scope creep' and who gets to be called 'doctor'

Truvian presents data for its desktop blood

4th of July breaks record for highest global temperature ever measured

When is a doctor not a doctor? Try when patients address women doctors

hotspot

knowledge

explore

Affirmative action in medical school literally saved lives

CDC Director Mandy Cohen on transparency, trust, and health

Novavax promises a turnaround & Lilly roils the obesity market

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

Novavax promises a turnaround & Lilly roils the obesity market

A new crop of companies is reshaping the health data economy

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Bacterial infection may be ‘key event’ in endometriosis, study says

Psychedelics group wrestles with new pharma identity

Device maker Teleflex to acquire urology company for $600M

focus

A new study asks: Are we harming blood donors by taking blood?

How doctors’ personal politics affect patients

CDC Director Mandy Cohen on transparency, trust, and health

RaDonda Vaught case: a double standard for nurses, physicians

When is a doctor not a doctor? Try when patients address women doctors

Community addresses injustice for Long Island mothers

hotspot

focus

focus

entertainment